Hidroferol Wekelijks

Hidroferol Wekelijks is an oral, over‑the‑counter vitamin D supplement whose active ingredient is calcifediol monohydrate. The product is marketed in the European Union and is supplied in a weekly dosage form, although the exact strength is not specified on the label. Calcifediol is a direct precursor of the circulating form of vitamin D and is used to support normal calcium and phosphate metabolism in the body.

Hidroferol Wekelijks is indicated for the prevention and treatment of vitamin D deficiency in individuals who require regular supplementation.

- Adults with low serum 25‑hydroxyvitamin D levels. - Children and adolescents with documented deficiency. - Patients with conditions that limit cutaneous vitamin D synthesis, such as limited sun exposure or malabsorption. - Individuals at risk of osteomalacia or rickets due to inadequate vitamin D intake. - Elderly persons with reduced dietary vitamin D intake.

Adverse reactions to Hidroferol Wekelijks are generally mild, but rare serious events have been reported.

Common: - Mild gastrointestinal discomfort such as nausea, abdominal cramping, or loss of appetite. - Transient headache that resolves without intervention. - Slight, asymptomatic increase in serum calcium levels detected on routine testing. - General fatigue or drowsiness, especially after the first weekly dose.

Serious: - Clinically significant hypercalcemia manifested by excessive thirst, frequent urination, constipation, or cardiac rhythm disturbances. - Allergic reactions ranging from skin rash and pruritus to angioedema and, rarely, anaphylaxis. - Development of renal calculi in patients with pre‑existing risk factors for stone formation. - Severe hypervitaminosis D leading to ectopic calcification in soft tissues, including blood vessels and the kidneys.

Precautions for using Hidroferol Wekelijks focus on patient conditions that may affect vitamin D metabolism or increase the risk of calcium imbalance.

- Assess baseline serum 25‑hydroxyvitamin D and calcium before initiating therapy. - Use with caution in patients with renal impairment, hyperparathyroidism, or granulomatous diseases. - Avoid in individuals with known hypersensitivity to calcifediol or any excipients. - Monitor calcium and phosphate levels periodically during long‑term use. - Consider dose adjustment or medical supervision in elderly patients or those taking multiple supplements. - Do not exceed the recommended weekly dose without physician guidance.

Hidroferol Wekelijks can interact with certain medicines that influence calcium balance or vitamin D metabolism.

Avoid: - Concomitant use with high‑dose vitamin D supplements that could cause excessive serum 25‑hydroxyvitamin D. - Co‑administration with thiazide diuretics, which may increase the risk of hypercalcemia.

Use with caution: - Calcium carbonate or other calcium‑containing antacids, as they may augment calcium absorption. - Bisphosphonates or denosumab, because combined effects on bone turnover require monitoring. - Corticosteroids, which can impair vitamin D activation and alter calcium homeostasis. - Certain anticonvulsants (e.g., phenytoin, phenobarbital) that increase vitamin D catabolism. - Orlistat, which may reduce absorption of fat‑soluble vitamins including vitamin D.